Navigation Links
Taiho Pharmaceutical presenta una solicitud para fabricar y comercializar el nuevo agente antitumoral TAS-102
Date:2/26/2013

tralia. La reclutación de pacientes comenzó en junio de 2012. Los sujetos son pacientes con cáncer colorrectal no reseccionable, avanzado y recurrente que rechaza las quimioterapias estándares (fluoropirimidina, irinotecan, oxaliplatin, bevacizumab, y anticuerpo monoclonal EGFR en casos de tumor de tipo no mutado KRAS). El ensayo comparará a los pacientes aleatoriamente asignados para recibir TAS-102 o placebo para investigar la eficacia y seguridad de TAS-102. La medida de evaluación principal es la supervivencia general. Los principales investigadores son el doctor Atsushi Otsu , director del Clinical Development Center del National Cancer Center Hospital East (Japón), el doctor Robert J. Mayer del Dana Farber Cancer Institute (USA), y el doctor Eric Van Cutsem del University Hospital Gasthuisberg (Bélgica).

Acerca de Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical, una filial de Otsuka Holdings Co., Ltd. (http://www.otsuka.com/en/), es una compañía farmacéutica de I+D centrada en los tres campos de oncología, alergias e inmunología, y urología. Su filosofía corporativa es una promesa: "Nos esforzamos por mejorar la salud humana y contribuir al enriquecimiento de la sociedad." En particular, en el campo de la oncología, Taiho Pharmaceutical es conocida como una compañía líder en Japón y en todo el mundo por el desarrollo de medicinas basadas en la evidencia para el tratamiento del cáncer. Además, en otras áreas distintas a la oncología, la compañía crea productos de calidad que tratan las enfermedades médicas de forma efectiva y pueden ayudar a mejorar la calidad de vida de las personas. Poniendo siempre al cliente en primer lugar, Taiho Pharmaceutical también pretende ofrecer productos médicos de
'/>"/>

SOURCE Taiho Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
3. Taiho Pharmaceutical présente une demande dhomologation pour la fabrication et la commercialisation du nouvel agent antitumoral TAS-102
4. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
5. Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Cowen & Company 33rd Annual Health Care Conference In Boston On March 5, 2013
7. Global Pharmaceutical Industry Trends: Procurement Budgets Stay the Same, Marketing Budgets to Experience Slight Decrease
8. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
9. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
10. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
11. UBM Launches PharmaEvolution.com, an Online Peer-to-Peer Network for Pharmaceutical Industry Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... that the company,s Bridgewater, New Jersey ... Food and Drug Administration (FDA) relating to an inspection ... to Sculptra Aesthetic injectable, which was divested to Galderma ... management of Valeant,s contract manufacturers (rather than Valeant,s own ...
(Date:9/30/2014)... 30, 2014 The Eastern European medical device ... providers as well as new medical-device manufacturers are constantly ... looking at ways to reduce the cost incurred for ... one of the effective means to achieve this target. ... in Eastern European and provides profiles of key distributors ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... on 01/05/2012 of Santa Barbara physician Dr. Julio Diaz ... overdose deaths from prescription medications. According to one of ... centers, Dr. Diaz,s arrest points to the dangers both ... of finding a physician who will prescribe medication for ...
... PHILADELPHIA, January 10, 2012 Shire plc (LSE: ... company, announced today that it has acquired the rights to ... States (US) in an agreement  with Janssen Pharmaceutica N.V.  Terms ... a prokinetic, is part of Shire,s gastrointestinal (GI) portfolio in ...
Cached Medicine Technology:Arrest of California Doctor Coincides with Uptick in Prescription Drug Overdoses 2Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... for doctors to measure damaging "brain tsunamis" in ... a step closer to reality, thanks to pioneering ... Institute. , The research team, led by Jed ... of neurosurgery at the UC College of Medicine, ... through an injured brain like tsunami wavescan be ...
(Date:9/30/2014)... 30, 2014 Keystone Symposia will convene the first ... its 2014-15 Global Health Series on "The Modes ... Hotel immediately following the conclusion of the Grand ... is part of the Keystone Symposia Global Health Series, ... has also funded travel awards for 36 investigators from ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new ... at higher rates than other primary care practices ... according to results of a new 10-state University ... Medical Care . , Using data from a ... 2013, the investigators found that FQHCs community ...
(Date:9/30/2014)... EverStryke , the permanent match currently offered by ... a free book and class all about survival education and ... investigative review. , “Joe Marshall of SurvivalLife.com is one ... niche, and this product is an excellent way to get ... that Joe offers on his website to help people be ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2
... research published in the December issue of the ... that the American College of Surgeons National Surgical Quality ... assessing outcomes of uncommon, high-risk surgical procedures, including pancreatic ... on this particular procedure has been available and analyzed, ...
... finding a cure for amyotrophic lateral sclerosis (ALS, or ... to help more researchers identify treatment candidates that increase ... The Jackson Laboratory will provide the most widely used ... work with them, to researchers participating in the Prize4Life ...
... ... getting recommended eye exam; EyeSmart: EyeCommitted social media campaign seeks to reduce the largest ... ... more new cases of legal blindness among working-age Americans than any other disease. If ...
... , ST. LOUIS, Dec. 10 Centene Corporation (NYSE: ... release its 2010 financial guidance at approximately 6:00 AM (Eastern ... call afterwards at approximately 8:30 AM (Eastern Time) to discuss ... Chief Executive Officer, and William N. Scheffel, Executive Vice President, ...
... , CINCINNATI, Dec. 10 Streamline Health Solutions, ... document workflow solutions for hospitals, today announced that St. ... Health to provide a workflow solution to ensure compliance ... (VPP) promotes effective worksite-based safety and health. St. Vincent,s ...
... ... Home Care as well as one system encompassing virtually every clinical, operational and financial aspect ... , ... 10, 2009 -- Fastrack Healthcare Systems announced today the completion of the first phase ...
Cached Medicine News:Health News:Surgical quality program is a strong tool for assessing outcomes for high-risk procedures 2Health News:Prize4Life and the Jackson Laboratory team up to fight ALS 2Health News:Prize4Life and the Jackson Laboratory team up to fight ALS 3Health News:Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam 2Health News:Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam 3Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 2Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 3Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 2Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 3Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 4Health News:Fastrack Announces Major Expansion 2Health News:Fastrack Announces Major Expansion 3
The extended lip of the lower jaw assists in placing the lower jaw underneath less-mobile menisci....
The Smith & Nephew ACUFEX DUCKLING punches are a lower-profile relation to the Duckbill, maintaining a large square bite and maximizing maneuverability....
For the specific requirements of the posterior horn of the meniscus; the short, low profile jaw facilitates working in the tight confines of the posterior aspect of the knee....
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
Medicine Products: